Bempedoic acid in a high-risk primary-prevention patient unable to take statins: a case-based approach

Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better. Am J Prev Cardiol 2024; 18: 100649.

Google Scholar

Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61.

Google Scholar

Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026; 407: 689-703.

Google Scholar

Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022; 43: 3213-23.

Google Scholar

Stürzebecher PE, Gouni-Berthold I, Mateev C, et al. Quality of life in patients with statin intolerance: a multicentre prospective registry study. Lancet Reg Health Eur 2024; 43: 100981.

Google Scholar

Stürzebecher PE, Schneider T, Gouni-Berthold I, et al. One-year treatment trajectories of patients with statin intolerance: results from a multicentre registry. Eur J Prev Cardiol 2025: zwaf619. doi: 10.1093/eurjpc/zwaf619.

CrossRef

Google Scholar

Zimodro JM, Gouni-Berthold I. Bempedoic acid: from guidelines to the real world. J Lipid Atheroscler 2026; 15: e29.

Google Scholar

Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46: 4359-78.

Google Scholar

Banach M, Penson PE. Drucebo effect – the challenge we should all definitely face! Arch Med Sci 2021; 17: 542-3.

Google Scholar

10.

Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle 2018; 9: 1023-33.

Google Scholar

11.

Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-22.

Google Scholar

12.

Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23.

Google Scholar

13.

Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol 2016; 32 (7 Suppl): S35-65.

Google Scholar

14.

Sposito AC, Faria Neto JR, Carvalho LS, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin 2017; 33: 239-51.

Google Scholar

15.

Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol 2022; 16: 361-75.

Google Scholar

16.

Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) J Cachexia Sarcopenia Muscle 2022; 13: 1596-622.

Google Scholar

17.

Stürzebecher PE, Katzmann JL, Gouni-Berthold I, et al. Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: insights from the multicentre statin intolerance registry. Am J Prev Cardiol 2025; 21: 100953.

Google Scholar

18.

Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis 2023; 79: 2-11.

Google Scholar

19.

Patel SB, Wyne KL, Afreen S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract 2025; 31: 236-62.

Google Scholar

20.

Laufs U, Ballantyne CM, Banach M, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol 2022; 16: 286-97.

Google Scholar

21.

Katzmann J, Becker C, Schneider T, Articus K, Keuken G, Laufs U. Real-world effectiveness of bempedoic acid in reducing LDL-C: an electronic medical records-based analysis. JACC Adv 2026; 5: 102726.

Google Scholar

22.

Warden BA, Cardiology BA, Purnell JQ, Duell PB, Fazio S. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol 2022; 16: 94-103.

Google Scholar

23.

Ballantyne CM, Bays HE, Louie MJ, Smart J, Zhang Y, Ray KK. Factors associated with enhanced low-density lipoprotein cholesterol lowering with bempedoic acid. J Am Heart Assoc 2022; 11: e024531.

Google Scholar

24.

Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388: 1353-64.

Google Scholar

25.

Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA 2023; 330: 131-40.

Google Scholar

26.

Bays HE, Bloedon LT, Lin G, et al. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance. J Clin Lipidol 2024; 18: e59-69.

Google Scholar

27.

Ray KK, Nicholls SJ, Lincoff AM, et al. Association of uric acid-lowering therapies on gout frequency with bempedoic acid: clinical insights from CLEAR outcomes. JACC Adv 2025; 4: 102207.

Google Scholar

28.

Nilemdo. Summary of product characteristics. Available online: https://www.ema.europa.eu/en/m.... Accessed: May 12, 2026.

Google Scholar

Submit your paper

eISSN:	1896-9151
ISSN:	1734-1922